License agreement for efarindodekin alfa and stock purchase by Gilead of common stock and prefunded warrants in three private placements
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
René Russo
Also a director
President, Chief Executive Officer and Director
|
51 | Not stated | $6,451,495 | |
|
Christopher Frankenfield
Chief Financial and Operating Officer
|
44 | Not stated | $3,229,346 | |
|
Katarina Luptakova
Chief Medical Officer
|
50 |
Since 2023
3 years
|
$2,197,248 | |
|
Yariv Houvras
CHIEF MEDICAL OFFICER
Title from the Form 4 dated Oct 1, 2026
|
Not stated | Not stated | Not reported | |
|
Kevin Brennan
Senior Vice President, Finance and Accounting
|
56 |
Since 2023
3 years
|
Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 28, 2026 · updated by the 8-K of Jun 12, 2026
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
License agreement for efarindodekin alfa and stock purchase by Gilead of common stock and prefunded warrants in three private placements
Purchase of prefunded warrants in the April 2024 private placement
Purchase of common stock in the April 2024 private placement
Collaboration, license and option agreement and purchase of 310,559 shares of common stock in a private placement at $32.20 per share
Purchase of prefunded warrants with series A, B and C warrants in the June 2025 follow-on offering
Purchase of prefunded warrants in the February 2026 follow-on offering
Purchase of prefunded warrants in the February 2026 follow-on offering
Purchase of prefunded warrants in the February 2026 follow-on offering
Purchase of prefunded warrants in the February 2026 follow-on offering
Loading...